Edition:
United States

CymaBay Therapeutics Inc (CBAY.OQ)

CBAY.OQ on NASDAQ Stock Exchange Capital Market

8.58USD
22 Nov 2017
Change (% chg)

$-0.13 (-1.49%)
Prev Close
$8.71
Open
$8.71
Day's High
$8.84
Day's Low
$8.55
Volume
76,862
Avg. Vol
263,361
52-wk High
$9.40
52-wk Low
$1.46

Select another date:

Wed, Nov 8 2017

BRIEF-CymaBay reports Q3 loss per share $0.21

* CymaBay reports third quarter 2017 financial results and corporate updates

BRIEF-Cymabay to deliver interim results from ongoing phase 2 study of Seladelpar at AASLD 2017

* Cymabay announces oral late-breaking presentation of interim results from an ongoing Phase 2 study of patients with primary biliary cholangitis at the AASLD 2017 Liver Meeting

BRIEF-CymaBay Therapeutics granted EMA orphan drug designation for seladelpar

* CymaBay Therapeutics granted EMA orphan drug designation for seladelpar for the treatment of primary biliary cholangitis Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics publishes Seladelpar proof-of-concept study

* Cymabay Therapeutics announces the publication of the Seladelpar proof-of-concept study for primary biliary cholangitis in lancet gastroenterology and hepatology

BRIEF-CymaBay Therapeutics reports Q2 loss per share $0.31

* CymaBay reports second quarter 2017 financial results and provides corporate update

BRIEF-CymaBay announces pricing of public offering of common stock

* CymaBay announces pricing of public offering of common stock

BRIEF-Cymabay announces proposed public offering of 10.0 mln common shares

* Cymabay Therapeutics Inc - anticipates using net proceeds from offering to fund ongoing development of seladelpar

BRIEF-CymaBay announces positive interim results from low-dose phase 2 study of seladelpar

* CymaBay announces positive interim results from its ongoing low-dose phase 2 study of seladelpar in patients with primary biliary cholangitis

Select another date: